Tilray Medical, a division of Tilray Brands, Inc., announced on January 6 that its German subsidiary, Tilray Deutschland GmbH, has secured a tender to supply Luxembourg with its cannabis flower.
“We are honored to have been selected again to supply medical cannabis to Luxembourg,” said Denise Faltischek, CSO at Tilray and Head of International at Tilray Brands, in a company press release. “This is a testament to the unwavering dedication of our team in providing patients around the world with high-quality medical cannabis products.”
Luxembourg’s Ministry of Health and Social Security has authorized qualified health professionals to prescribe medical cannabis as a treatment option since February 2019. In a post on its website, the agency says that as of January 1, 2025, THC-rich flowering tops will no longer be available, but patients will still have access to CBD-rich cannabis flower and “balanced” THC and CBD flower, along with cannabis oil.
Access to these products has been increasing since the program was introduced. There were 18 bottles of cannabis oil prescribed in 2022, 2,043 bottles in 2023, and 2,850 since January 2024, which has also contributed to the adjustment of the program. The population of Luxemburg is around 675,000 people.
In October 2024, the city released tenders for cannabis oil (“THC dominant”, “CBD dominant” and “THC/CBD balanced”) and medicinal cannabis in the form of dried flowering tops (“CBD dominant” and “THC/CBD balanced”).
In November 2024, Tilray Medical launched its first commercial-grown medical cannabis flowers from its Aphria RX GmbH facility in Germany.
Source
Tilray Medical wins tender to supply Luxembourg with medical cannabis
